Related Experiment Video
Updated: Apr 25, 2026
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
14.6K
Prostate stem cell antigen rs2294008 (C>T) polymorphism and bladder cancer risk: a meta-analysis based on cases and
1Department of Urology, Xuzhou 3th Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.
Genetics and Molecular Research : GMR
|August 14, 2014
Summary
The prostate stem cell antigen (PSCA) rs2294008 (C>T) gene variant increases bladder cancer risk. This meta-analysis confirms its role as a significant risk factor in various populations.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- The association between the prostate stem cell antigen (PSCA) rs2294008 (C>T) polymorphism and bladder cancer risk has been investigated in several studies.
- Previous findings on this association remain inconclusive, necessitating further comprehensive analysis.
Purpose of the Study:
- To conduct a meta-analysis to precisely estimate the association between the PSCA rs2294008 (C>T) polymorphism and bladder cancer susceptibility.
- To consolidate evidence from existing case-control studies to provide a more robust conclusion.
Main Methods:
- A meta-analysis was performed on four case-control studies.
- Data included 9617 cases and 16,323 controls.
- Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the risk association.
Main Results:
- The meta-analysis revealed a significant association between the rs2294008 (C>T) polymorphism and increased bladder cancer susceptibility.
- Specific genotype comparisons showed increased risk for TT vs CC (OR=1.29), CT vs CC (OR=1.24), and TT/CT vs CC (OR=1.25).
- Stratified analyses indicated consistent risk elevation in European and Asian populations, as well as in both population-based and hospital-based studies.
Conclusions:
- The PSCA rs2294008 (C>T) polymorphism is a confirmed risk factor for bladder cancer development.
- The findings highlight the importance of this genetic variant in bladder cancer etiology across diverse populations.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
01:05Single Nucleotide Polymorphisms-SNPs
14.4K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.4K